trending Market Intelligence /marketintelligence/en/news-insights/trending/CdfH6DLeLMuwYJLxjD4f_Q2 content esgSubNav
In This List

Former FDA commissioner joins Malin as chief medical adviser

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Former FDA commissioner joins Malin as chief medical adviser

Malin Corp. PLC appointed Andrew von Eschenbach to serve as chief medical adviser.

Von Eschenbach was previously an advisory partner to Malin. He served as the commissioner of the U.S. Food and Drug Administration from 2006 to 2009. Prior to that, he was the director of the National Cancer Institute at the National Institute of Health.

Von Eschenbach is the president of Samaritan Health Initiatives Inc.